Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Merck

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times

50 Top Companies By Market Capitalization: The Global Giants

These companies are the ones that dominate the market and will continue to do so should factors remain constant.

International Business Times

Rachel Nuwer: MDMA Is On the Cusp of Legalization

In 2024, the FDA will decide whether or not MDMA can be used to treat patients suffering from PTSD.

Reason

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck (MRK): Quarterly Earnings - What Investors Should Know

Pharma giant Merck (MRK) has an impressive record of surpassing analysts’ expectations in its top and bottom lines. So, is the company on track to top estimates in the upcoming earnings release? Let’s discuss some of its financials to gauge its prospects.

StockNews.com

Merck, Johnson & Johnson CEOs agree to appear before Senate HELP - Roll Call

Two drug company CEOs have agreed to testify before the Senate HELP Committee on drug prices, avoiding a scheduled subpoena vote on Jan. 31.

Roll Call

2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter

Five pharma companies will have sales that exceed $50 billion this year.

Kiplinger

Cyberwar continues to underperform

Episode 487 of the Cyberlaw Podcast

Reason

Read news from The Economist, FT, and more,
with one subscription

Merck Hooks Harpoon Therapeutics in 0M Acquisition Spree!

Merck sets sail into new therapeutic waters with the 0 million acquisition of Harpoon Therapeutics, harnessing the power of innovation to navigate treat...

Top News

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com

Looking back on the challenges CEOs faced in 2023, from war to climate change to the A.I. boom

Looking ahead, 2024 likely will be filled with volatility, uncertainty, complexity, and ambiguity. That’s "VUCA" for you.

Fortune

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com

Former Merck CEO Ken Frazier on the responsibility of CEOs to uphold principles despite politics

Plus: Frazier talks about the shareholders who trusted his vision enough to support him in his early days at the helm.

Fortune

The 3 Best Dow Jones Stocks to Invest in Now, According to Wall Street

Analysts are bullish on these three dividend-paying Dow stocks, with consensus "Strong Buy" ratings and more upside expected for this diverse set of blue chips.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Ex-Merck CEO Ken Frazier says CEOs must uphold American values

Frazier was one of the first CEOs to publicly distance himself from President Donald Trump.

The Independent UK

COVID-19 treatments to enter the market with a hefty price tag

The COVID-19 treatments millions of have taken for free from the federal government will enter the private market next week with a hefty price tag

Barchart

3 Beaten-Down Dow Stocks to Buy in October

Dow Jones industrials, such as Nike, have pulled back significantly amid recent market turmoil, and now trade at a steep discount to consensus price target estimates.

WEKU

All in: Drugmakers say yes, they'll negotiate with Medicare on price, so reluctantly

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Former Merck boss Ken Frazier wants CEOs to speak out

In a politicized world, the former Merck boss says CEOs should stand up and speak out. “Pick your spots.”

Barchart

How To Buy MRK For A 5% Discount, Or Achieve An 13% Annual Return

Yesterday, with Merck trading at $103.94, the November put option with a strike price of $100 was trading around $1.78. Traders selling this put would receive $178 in option premium.

Salon

Amy Klobuchar on Biden's biggest win

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody

Fortune

Managers say they support skills-based hiring. But many jobs still require 4-year degrees

Just over half of hiring managers say removing four-year degree requirements would positively impact their company's hiring practices, according to a OneTen report.

The Guardian - US

Biden names 10 drugs for first negotiations to cut Medicare prices

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Fortune

Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial Medicare price talks. But any relief is still years away

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

Chicago Sun-Times

Biden targets Jardiance, Eliquis and 8 other prescription drugs for Medicare price talks

President Joe Biden says for many Americans the cost of one drug can be “the difference between life and death” as his administration announces the first drugs that’ll be targeted for price negotiations in an effort to cut Medicare costs.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.